Synergy Pharma continues to grow extended prescription units for Trulance.
Competitor drug Linzess produced a highly profitable Q4.
Trulance prescription growth appears to lag the revenue estimates, especially in Q1.
With financing in place and a spring ramp in prescriptions, the stock is positioned for buying any weakness related to missing revenue targets.
With all of the drama surrounding executive leadership and cash burn at Synergy Pharma (SGYP), the market hasn't focused as much on the prescription data of Trulance. The stock has held close to $2 suggesting healthy investor appetite for the biotech at this level, but meeting 2018 targets could create further weakness in Synergy Pharma providing an opportunity to own the stock at lower prices.